Literature DB >> 17968303

Hypercalcemia as a result of sarcoidosis with normal serum concentrations of vitamin D.

Stefan Falk1, Juergen Kratzsch, Ralf Paschke, Christian A Koch.   

Abstract

BACKGROUND: Hypercalcemia can occur in patients with granulomatous disorders such as sarcoidosis, and is commonly related to high serum 1,25-dihydroxyvitamin D (OHD) concentrations. CASE REPORT: We here report a 68-year-old man with a history of mild renal insufficiency who presented with hypercalcemia (serum calcium of 3.11 mmol) and normal 1,25-OHD levels (38 pg/ml, RIA/IDS, Boldon, UK, measuring both 1,25-OH D2 and D3). Imaging and laboratory investigations were suggestive of sarcoidosis. After hydration and prednisone therapy (40 mg/day) for 7 days, serum calcium dropped to 2.7 mmol and 1,25-OHD levels to 13.4 pg/ml. Six weeks after prednisone therapy, serum calcium was 2.41 mmol (normal) and 1,25-OHD 6.2 pg/ml (low). Computed tomography of the chest showed shrinkage of the right hilar mass.
CONCLUSIONS: This case illustrates that hypercalcemia can occur in granuloma-forming disorders such as sarcoidosis in the setting of inappropriately normal (and not elevated) 1,25-OHD levels. Contributing factors may include dehydration, increased uptake of oral calcium and/or decreased calcium excretion, especially in mild renal insufficiency. Therapy of choice are hydration and glucocorticoid (prednisone) therapy. In this setting, prednisone may lead to a decline of activated mononuclear cells (in the lung and lymph nodes) that are able to produce extrarenal PTH-independent 1,25-OHD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17968303

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  11 in total

1.  Solar ultraviolet-B irradiance and vitamin D may reduce the risk of septicemia.

Authors:  William B Grant
Journal:  Dermatoendocrinol       Date:  2009-01

2.  New light on an old vitamin: The role of the sunshine vitamin D in chronic disease.

Authors:  Christian A Koch
Journal:  Rev Endocr Metab Disord       Date:  2017-06       Impact factor: 6.514

3.  A curious case of growth failure and hypercalcemia: Answers.

Authors:  Mallory L Downie; Jaap Mulder; Rayfel Schneider; Lillian Lim; Nasrin Tehrani; Jonathan D Wasserman; Shai Fuchs; Rohan John; Damien G Noone; Diane Hebert
Journal:  Pediatr Nephrol       Date:  2017-08-07       Impact factor: 3.714

Review 4.  The paradoxical effects of vitamin D on type 1 mediated immunity.

Authors:  Margherita T Cantorna; Sanhong Yu; Danny Bruce
Journal:  Mol Aspects Med       Date:  2008-05-04

5.  Hypercalcemia in a patient with disseminated paracoccidioidomycosis: a case report.

Authors:  Rafael Moura Almeida; Loureno Cezana; Daniela Miti Lemos Tsukumo; Marco Antônio de Carvalho-Filho; Mário José Abdalla Saad
Journal:  J Med Case Rep       Date:  2008-08-08

6.  Mirror, mirror on the wall: hypercalcemia as a consequence of modern cosmetic treatment with liquid silicone.

Authors:  Jurik Schanz; Katharina Flux; Claudia Kircher; Maria Tsioga; Wolfgang Hartschuh; Peter P Nawroth; Gottfried Rudofsky
Journal:  Med Sci Monit       Date:  2012-02

7.  Cervical lymph node sarcoidosis mimicking a parathyroid adenoma: a clinical case.

Authors:  Pietro Giorgio Calò; Giuseppe Pisano; Alberto Tatti; Giulia Loi; Silvia Furcas; Angelo Nicolosi
Journal:  Clin Med Insights Case Rep       Date:  2013-10-16

8.  Rare association of thymoma, myasthenia gravis and sarcoidosis : a case report.

Authors:  Mohankumar Kurukumbi; Roger L Weir; Janaki Kalyanam; Mansoor Nasim; Annapurni Jayam-Trouth
Journal:  J Med Case Rep       Date:  2008-07-25

9.  [Nephrocalcinosis complicating miliary tuberculosis in an infant].

Authors:  Jaouad El Maghraoui; Fatima Zahrae Souilmi; Mohamed Hbibi; Tarik Sqalli Houssaini; Mustapha Hida
Journal:  Pan Afr Med J       Date:  2015-04-29

Review 10.  Sarcoidosis and calcium homeostasis disturbances-Do we know where we stand?

Authors:  Łukasz Gwadera; Adam Jerzy Białas; Mikołaj Aleksander Iwański; Paweł Górski; Wojciech Jerzy Piotrowski
Journal:  Chron Respir Dis       Date:  2019 Jan-Dec       Impact factor: 2.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.